Takeda logo



November 7, 2019

当社は、このたび、2019年12月7日から10日にかけて米国フロリダ州オーランドで開催される第61回米国血液学会年次総会(American Society of Hematology:ASH)において、全29件(オンコロジー20件、血液疾患9件)の発表を行いますのでお知らせ致します。



ニンラーロ (一般名:イキサゾミブクエン酸エステル) および多発性骨髄腫

  • Primary Results from the Phase 3 TOURMALINE-AL1 Trial of Ixazomib-Dexamethasone Versus Physician’s Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL). 抄録番号139、オーラルプレゼンテーション
  • Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice Remain Comparable to the Outcomes Reported in the Phase 3 TOURMALINE-MM1 Study. 抄録番号1845、ポスター発表

  • Real-World (RW) Multiple Myeloma (MM) Patients (Pts) Remain Under-Represented in Clinical Trials Based on Standard Laboratory Parameters and Baseline Characteristics: Analysis of Over 3,000 Pts from the Insight MM Global, Prospective, Observational Study. 抄録番号1887、ポスター発表

  • Long-Term Proteasome Inhibitor (PI) Therapy in Community Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (Btz)-Based to Ixazomib-Based Induction: Results from the US MM-6 Study in the Real World (RW) Setting. 抄録番号1882、 ポスター発表

  • Real-World (RW) Treatment Patterns and Patient-Related Factors Including Quality of Life (QoL), Medication Adherence, and Actigraphy in Community Patients with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (btz) to Ixazomib: The US MM-6 Community-Based Study. 抄録番号3168、ポスター発表

  • Comparative Effectiveness of Triplets Containing Bortezomib (V), Carfilzomib (K), or Ixazomib (I) Combined with a Lenalidomide and Dexamethasone Backbone (Rd) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) in Routine Care in the United States (US). 抄録番号182、ポスター発表

  • Evolving Real-World Treatment Patterns in Patients with Newly-Diagnosed Multiple Myeloma (NDMM) in the United States (U.S.). 抄録番号3164、ポスター発表

  • Evolving Treatment Trends in Relapsed/Refractory Multiple Myeloma (RRMM) in Europe from 2016 to 2018: Analysis of a Multi-National Survey. 抄録番号3115、ポスター発表

アドセトリス(一般名:ブレンツキシマブ ベドチン)および リンパ腫

  • Brentuximab Vedotin with Chemotherapy for Stage III/IV Classical Hodgkin Lymphoma (HL): 4-Year Update of the ECHELON-1 Study. 抄録番号4026、ポスター発表

  • An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell Transplant. 抄録番号464、オーラルプレゼンテーション

  • Patterns of Care and Clinical Outcomes in Peripheral T-Cell Lymphoma Patients Receiving First-Line Treatment in Routine Clinical Practice in France and the United Kingdom. 抄録番号3482、ポスター発表

  • Real-World Treatment Patterns and Overall Survival Among Medicare Fee-For-Service Beneficiaries Newly Diagnosed with Peripheral T-cell Lymphoma (PTCL). 抄録番号3492、ポスター発表



  • Major Adverse Cardiac, Arterial Occlusive, and Venous Occlusive Events Among Chronic Myeloid Leukemia Patients Prescribed Ponatinib Vs Bosutinib. 抄録番号4751、ポスター発表



  • A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Who Are Proteasome Inhibitor (PI)- and Immunomodulatory Drug (IMiD)-Refractory, Including Pts Relapsed/Refractory (R/R) or Naïve to Daratumumab (dara). 抄録番号1867、ポスター発表

  • The Binding of CD38 Therapeutics to Red Blood Cells and Platelets Subverts Depletion of Target Cells. 抄録番号3136、ポスター発表

  • Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM). 抄録番号140、オーラルプレゼンテーション

  • Phase 1b/2 Study of TAK-981, a First-in-Class SUMOylation Inhibitor in Combination with Rituximab in Patients with Relapsed/Refractory (R/R) CD20-Positive Non-Hodgkin Lymphoma (NHL). 抄録番号1593、ポスター発表

  • Neddylation Pathway Regulates Treg Differentiation and T-Cell Function in Chronic Lymphocytic Leukemia (CLL) in Human Ex Vivo and Murine in Vivo Studies. 抄録番号4313、ポスター発表

  • Pharmacologic Inhibition of SUMO-Activating Enzyme (SAE) with TAK981 Augments Interferon Signaling and Regulates T-Cell Differentiation in Ex Vivo Studies of Chronic Lymphocytic Leukemia (CLL). 抄録番号1760、ポスター発表

  • Targeting Hypersumoylation in Mantle Cell Lymphoma. 抄録番号 4060、ポスター発表


アディノベイト(血液凝固因子(ペグ化遺伝子組換え)) および血友病A

  • Cost-Effectiveness Model of Recombinant FVIII Versus Emicizumab Treatment of Patients With Severe Hemophilia A Without Inhibitors. 抄録番号2102、ポスター発表

  • Real-World Age-Stratified FVIII Consumption and Bleed Outcomes Before and After Switching to Rurioctocog Alfa Pegol in a Retrospective, Observational Study Using US Specialty Pharmacy Data. 抄録番号2411、ポスター発表



  • Real-World Clinical Management of Patients with Hemophilia and Inhibitors: Effectiveness and Safety of aPCC in Patients with >18 Months’ Follow-up in the FEIBA Global Outcome Study (FEIBA GO). 抄録番号2418、ポスター発表



  • Analysis of Bleeding and Treatment Patterns in Children and Adolescents before and after von Willebrand Disease Diagnosis Using Data from a US Medical Claims Database. 抄録番号2102、ポスター発表

  • Estimation of the Economic Burden Associated with Major Surgery Due to von Willebrand Disease Based on Claims Data from the USA. 抄録番号4692、ポスター発表



  • Co-Prevalence of Pre-Existing Immunity to Different Serotypes of Adeno-Associated Virus (AAV) in Adults with Hemophilia. 抄録番号3349、ポスター発表

  • Evaluation of the Human Factor IX Gene Therapy Vector TAK-748 in Hemophilia: Results from Non-Clinical Studies in Factor IX Knockout Mice and Rhesus Monkeys. 抄録番号4633、ポスター発表

  • AAV8-Specific Immune Adsorption Column: A Treatment Option for Patients with Pre-Existing Anti-AAV8 Neutralizing Antibodies. 抄録番号5922、ポスター発表

  • The Factor VIII Variant X5 Enhances Hemophilia A Gene Therapy Efficiency by Its Improved Secretion. 抄録番号 3356、 ポスター発表